RecruitingMantle Cell Lymphoma (MCL)
A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to understand the long-term safety and effectiveness of lisocabtagene maraleucel (liso-cel) for the treatment of Mantle Cell Lymphoma (MCL).
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
You may qualify if…
- ✓ Participants must have been treated in the postmarketing setting with at least 1 infusion of lisocabtagene maraleucel (Liso-cel) used for the treatment of Mantle Cell Lymphoma (MCL) according to the FDA-approved indication and dose range (ie, per the US Prescribing Information) and with a product meeting the specifications for commercial release approved in the USA
You may not qualify if…
- ✕ Participants known to be participating in investigational studies at the time of liso-cel infusion.
- ✕ Participants treated with non-conforming CAR T-cell product.
Where it's recruiting
Wisconsin
Milwaukee
Source: ClinicalTrials.gov · NCT06788652 · last updated 2025-02-24